ERBB2 and breast carcinoma: But recently, revolutionizing the treatment paradigm, unresectable or metastatic HER2-low breast cancer that has previously been treated with chemotherapy can now be treated with Enhertu (fam-trastuzumab-deruxtecan-nxki), the first targeted therapy approved by U.S Food and Drug Administration (FDA) [2].